







Risks and Outcomes of Gastrointestinal Malignancies in Anticoagulated Atrial Fibrillation Patients Experiencing Gastrointestinal Bleeding – A Nationwide Cohort Study
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Background: Oral anticoagulants (OACs) may serve as a kind type of “stress screening test” for the diagnosis of occult gastrointestinal (GI) tract malignancies through the amplifications of a clinical presentation with bleeding. We aimed to investigate the 1-year incidence and predictors of GI cancers after GI bleeeding events among patients with atrial fibrillation (AF) treated with warfarin or NOACs. We Second, we also aimed to compare the risk of mortality after GI cancers between patients treated with warfarin or NOACs.
Methods: A total of 10,845 anticoagulated AF patients who experienced hospitalizations due to GI bleeding without priory history of GI cancers were identified from the Taiwan National Health Insurance Research Database. Patients were followed up for incident GI cancers for up to 1 year. 
Results: Within 1 year after GI bleeding, 290 (2.67%) patients were diagnosed to have GI tract cancers. More patients treated with NOACs were diagnosed to have GI cancers than those receiving warfarin (68/ in 1,759; 3.87% [NOACs] versus 222 in/ 9,086; 2.44% [warfarin], p<0.001) with an odds ratio (OR) of 1.606 (95% CI 1.208-2.117, p <0.001). Age (OR 1.025 (95%CI 1.012 – 1.037) per 1 year increment) and male sex (1.356 (95%CI 1.050 – 1.700)) were t independently associated with the diagnosis of GI cancers within 1 year after GI bleeding with an odds ratio of 1.025 (95%CI 1.012 – 1.037) per 1 year increment and 1.356 (95%CI 1.050 – 1.700), respectively. Among 290 patients diagnosed to have GI cancers, 131 (45.2%) of them experienced mortality within 1 year. The risk of mortality was lower for patients treated with NOACs compared to those receiving warfarin (23.5% versus 51.8%) with an adjusted hazard ratio (aHR) of 0.441 (95% CI 0.262 - 0.744, p<0.001).
Conclusions: Incident GI cancers were diagnosed in 2.67% (1 in 37) of  AF patients at 1 year after OAC-related GI bleeding, which were more common among patients treated with NOACs (1 in 26) compared to warfarin (1 in 41). Detailed surveys for occult GI cancers were necessary for these patients, especially for the elderly males.





Stroke prevention with oral anticoagulants (OACs) is the cornerstone of holistic management of atrial fibrillation (AF). ADDIN EN.CITE 1,2 Four pivotal randomized trials comparing warfarin and non-vitamin K antagonist OACs (NOACs) demonstrated that NOACs were at least as effective as warfarin for stroke prevention and much safer regarding the risk of intracranial hemorrhage. ADDIN EN.CITE 3 Unexpectedly, these trials showed that some NOACs were associated with an increased risk of major gastrointestinal (GI) bleeding in comparison with warfarin. ADDIN EN.CITE 3
Although patients treated with OACs are at risk of bleeding, bleeding may be the first manifestation of underlying cancer. In the previous studies on warfarin, most bleeding events occurred within the first year of therapy, ADDIN EN.CITE 4,5 and GI tract malignancies were related to the occurrences of GI bleeding. ADDIN EN.CITE 6-8 Furthermore, iIn a subgroup analysis of the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, 8.1% of major GI bleeding events was were found to be from GI cancers. ADDIN EN.CITE 9  Also, Clemens et al. reported that the higher incidence of GI bleeding with the NOACs might be related to pre-existing malignancies. ADDIN EN.CITE 10 In a recent analysis of COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) which enrolled patients with atherosclerosis treated with aspirin or rivaroxaban or both, GI cancers were diagnosed in around 9.5% of patients with major GI bleeding events. ADDIN EN.CITE 11 
Therefore, OACs may serve as a kind of “stress screening test” for the diagnosis of occult GI tract malignancies through a clinical presentation with bleeding. the amplifications of bleeding. However, these findings mainly came from randomized trials, and data in thefrom routine daily practice are limited.
In the present natiowide study, we investigated the 1-year incidence and predictors of GI cancers after GI bleeeding events among AF patients treated with warfarin or NOACs. We also aimed to compare the risk of mortality after GI cancers were diagnosed between patients treated with warfarin or NOACs. Second, we aimed to compare the risk of mortality after GI cancers between patients treated with warfarin or NOACs.
Methods
This study used the “National Health Insurance Research Database (NHIRD)” provided by the Health and Welfare Data Science Center (HWDC), Ministry of Health and Welfare (MOHW), Taiwan. The National Health Insurance (NHI) system is a mandatory universal health insurance program that offers comprehensive medical care coverage to all Taiwanese residents. NHIRD consists of detailed health care data from over 23 million enrollees, representing more than 99% of Taiwan’s population. In this cohort dataset, the patients’ original identification numbers have been encrypted to protect their privacy, but the encrypting procedure was consistent, so that a linkage of the claims belonging to the same patient was feasible within the NHI database and can be followed continuously. The descriptions about Taiwan NHIRD have been reported in our previous studies. ADDIN EN.CITE 12-19
Study cohort and study design
From January 1, 1996 to December 31, 2015, a total of 142,754 incident AF patients aged > 20 years receiving OACs were identified from NHIRD. AF was diagnosed using the International Classification of Diseases (ICD), Ninth Revision, Clinical Modification (ICD-9-CM) codes (427.31). To ensure the accuracy of diagnosis, we defined patients with AF only when it was a discharge diagnosis or confirmed for at least 2 times in the outpatient department. The diagnostic accuracy of AF using this definition in NHIRD has been validated previously. ADDIN EN.CITE 20 Among the study population, 11,632 patients experienced hospitalizations due to GI bleeding and 10,845 of them without priory history of GI tract cancers have constituted the study cohort. Patients were followed up for incident GI cancers up to 1 year. The flowchart of study design and the number of incident GI cancers diagnosed at 1 year after GI bleeding is shown in Figure 1. 
Predictors of GI cancers and risk of mortality after GI cancers were diagnosed
Factors associated with the occurrences of GI cancers within 1 year after the hospitalizations due to GI bleeding were analyzed. We also investigated the 1-year risk of all-cause mortality of patients after the diagnosis of GI tract cancers. The risk of mortality was compared between patients treated with warfarin or NOACs for all study period (1996-2015) and the era of NOACs (year 2012-2015). 
Statistical analysis




Clinical characteristics of patients with or without GI cancers within 1 year after GI bleeding
Within 1 year after GI bleeding, 290 (2.67%) patients were diagnosed to have GI tract cancers (esophageal cancer in 10, gastric cancer in 92 and colon cancer in 188) (Figure 2). More patients treated with NOACs were diagnosed to have GI cancers than those receiving warfarin (68 in/ 1,759; 3.87% [NOACs] versus 222/ in 9,086;  2.44% [warfarin], respectively; p<0.001) with an odds ratio of (OR) of 1.606 (95% CI 1.208-2.117, p <0.001)(Figure 2). 
Table 1 presents the characteristics of study population and patients with or without GI cancers within 1 year after GI bleeding. Patients diagnosed to have GI cancers were older (79.4 versus 77.0 yrs, p<0.001) and tended to have more males (59.7% versus 54.1%, p = 0.060) compared to those without GI cancers. There were no significant differences regarding comorbidities between the 2 groups, except for alcoholism. The CHA2DS2-VASc and HAS-BLED scores did not differ significantly. 
Risks and predictors of GI cancers
Factors associated with incident GI cancers after GI bleeding are shown in Table 2. Age (OR 1.025 (95%CI 1.012 – 1.037, p<0.001) per 1 year increment) and male sex (1.356 (95%CI 1.050 – 1.700, p = 0.018)0 were the only 2 factors independently associated with the diagnosis of GI cancers within 1 year after GI bleeding with an odds ratio of 1.025 (95%CI 1.012 – 1.037, p<0.001) per 1 year increment and 1.356 (95%CI 1.050 – 1.700, p = 0.018), respectively.
Figure 3 shows the percentages of patients diagnosed to have GI cancers within 1 year after GI bleeding,  stratified by age and gender. The percentages increased from 0.6% for patients aged < 50 years to 3.10% for those aged > 80 years. For males, the risk was higher among the elderly (age 70-79 years and > 80 years), while a higher risk of GI cancers was observed for females aged < 50 years and > 80 years. 
Risk of mortality after incident GI cancers were diagnosed





In this nationwide observational study, we investigated the risks, predictors and mortality of GI cancers revealed by GI bleeding associated with the use of warfarin or NOACs. Our principal findings are as follows: (i) at 1 year after GI bleeding, incident GI cancers were diagnosed in 2.67% of patients (1 in 37 (2.67%) treated with OACs; (ii) more patients treated with NOACs (3.87% [1 in 26; 3.87%]) were diagnosed to have GI cancers than those receiving warfarin (2.44% [1 in 41; 2.44%]); (iii) age and male gender were clinical factors associated with the diagnosis of GI cancers after GI bleeding; and (iv) the 1-year risk of all-cause mortality after GI cancers were lower among NOAC users who experienced GI bleeding than warfarin users.
Risk of GI cancers after GI bleeding 
GI bleeding could be the first sign of GI cancers among patients receiving antithrombotic drugs, including antiplatelet agents or warfarin. However, data regarding this issue in the era of NOACs were are relatively limited, and thewith only sub-analysis analyses of the RE-LY and COMPASS triaails represented 2 of them. ADDIN EN.CITE 9,11 Our study is the first non-trial report on this issue other than trials, and the number of patients (n = 10,845) with OAC-associated GI bleeding in our study was larger than that of the RE-LY (n = 546) or COMPASS (n = 296) trials. We demonstrated that 2.67% of patients who experienced GI bleeding were diagnosed to have GI cancers within the subsequent 1 year. The percentage (2.67%, 1 in 37) we observed was substantially lower than that of the RE-LY (8.1%, 1 in 12) and COMPASS (9.5%, 1 in 10) trials. ADDIN EN.CITE 9,11 It This may reflect the differences between the settings of clinical trials and routine daily practice. In the busy ‘real world’ daily practice, the clinical physicians may also miss to arrange surveys for occult GI cancers for patients suffering GI bleeding, and therefore, the attempts to improve the awareness of this issue is important. Clinical surveys should be performed to detect GI cancers especially for elderly males since age and male sex were factors significantly associated with the diagnosis of GI cancers after GI bleeding in our study.
      Interestingly, we demonstrated that patients treated with NOACs who experienced GI bleeding were more likely to be diagnosed to have GI cancers than warfarin. A possible explanation is that the international normalized ratios of warfarin iswere usually suboptimal in Asian AF patients, even in the randomized trials, ADDIN EN.CITE 21,22 and therefore, the “stress screening test” with warfarin for the diagnosis of occult GI malignancies through a clinical presentation with  the amplifications of bleeding may be less strong evident than compared to NOACs. AlsoFurthermore, dabigatran oral dabigatran ingestion would result in the presence of active intraluminal anticoagulant within the GI tract which may promote bleeding from friable GI cancers. ADDIN EN.CITE 9
Risk of mortality after GI cancers
A lower risk of mortality after GI cancers were diagnosed was observed for patients treated with NOACs compared to warfarin. Since NOACs were only available in Taiwan after year 2012, it is possible the treatments for GI cancers have improved and survivivial is s were better compared to the warfarin only era with warfarin only (before year 2012). However, eEven if we only compared the risk of mortality between patients treated with warfarin and NOACs from year 2012 to 2015, the risk of mortality was still lower for patients with GI cancer revealed by NOACs. AgainHence, NOACs may serve as a stronger “stress test” than warfain, and may be able to disclose GI cancers at a earlier stage, and leading therefore, to a better prognosis. 
Limitations
There are several limitations of the present study. First, it was a retrospective analysis of a nationwide insurance database, and there was no universal and pre-specified algorithm for the surveys of GI cancers for patients experiencing GI bleeding. Therefore, the percentages of GI cancers at 1 year after GI bleeidng we reported here could be underestimated. Second, although we have showed a lower risk of all-cause mortality after incident GI cancers revealed by NOAC-associated GI bleeding, data about the stages, detailed treatments of GI cancers and definite cause of mortality were not available in the registry database. Lastly, the present study only enrolled Taiwanses AF patients, and whether our findings could be explorated to other populations whose backgroud risks of GI cancers were different was uncertain.    
Conclusion 
Incident GI cancers were diagnosed in 1 in 37 AF patients at 1 year after OAC-related GI bleeding, which were more common among patients treated with NOACs (1 in 26) compared to warfarin (1 in 41). Detailed surveys for occult GI cancers were necessary for these patients, especially for the elderly males.





1. This work was supported in part by grants from the Ministry of Science and Technology (MOST 107-2314-B-075-062-MY3), Taipei Veterans General Hospital (V108B-015, V108B-027, V108C-090), Research Foundation of Cardiovascular Medicine and Szu-Yuan Research Foundation of Internal Medicine, Taipei, Taiwan.








1. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230-1239.2. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627-628.3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.4. Barada K, Abdul-Baki H, El H, II, Hashash JG, Green PH. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. Journal of clinical gastroenterology 2009;43:5-12.5. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328.6. Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987;83:269-272.7. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. The oncologist 2014;19:82-93.8. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.9. Flack KF, Desai J, Kolb JM, Chatterjee P, Wallentin LC, Ezekowitz M, Yusuf S, Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clinical gastroenterology and hepatology 2017;15:682-690.10. Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014;46:672-678.11. Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook-Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Ryden L, Verhamme P, Widimsky P, Zhu J, Yusuf S. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation 2019;140:1451-1459.12. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-1665.13. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642.14. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Chiang CE, Lip GY, Chen SA. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J Am Coll Cardiol 2015;66:1339-1347.15. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Chen TJ, Chiang CE, Chen SA. Rate-control treatment and mortality in atrial fibrillation. Circulation 2015;132:1604-1612.16. Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation 2016;133:1540-1547.17. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018;71:122-132.18. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation 2018;138:37-47.19. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. Eur Heart J 2019;40:1504-1514.20. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, Lin JW, Lai MS. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014;232:224-230.21. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S, Investigators R-L. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-1896.22. Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019;40:1518-1527.
2. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627-628.
3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
4. Barada K, Abdul-Baki H, El H, II, Hashash JG, Green PH. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. Journal of clinical gastroenterology 2009;43:5-12.
5. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328.
6. Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987;83:269-272.
7. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. The oncologist 2014;19:82-93.
8. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
9. Flack KF, Desai J, Kolb JM, Chatterjee P, Wallentin LC, Ezekowitz M, Yusuf S, Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clinical gastroenterology and hepatology 2017;15:682-690.
10. Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014;46:672-678.
11. Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook-Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Ryden L, Verhamme P, Widimsky P, Zhu J, Yusuf S. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation 2019;140:1451-1459.
12. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-1665.
13. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642.
14. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Chiang CE, Lip GY, Chen SA. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J Am Coll Cardiol 2015;66:1339-1347.
15. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Chen TJ, Chiang CE, Chen SA. Rate-control treatment and mortality in atrial fibrillation. Circulation 2015;132:1604-1612.
16. Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation 2016;133:1540-1547.
17. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018;71:122-132.
18. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation 2018;138:37-47.
19. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. Eur Heart J 2019;40:1504-1514.
20. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, Lin JW, Lai MS. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014;232:224-230.
21. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S, Investigators R-L. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-1896.




Table 1. Baseline characteristics of AF patients with or without incident GI tract cancers

	All(n=10,845)	With incident GI tract cancers(n=290)	Without incident GI tract cancers (n=10,555)	 P value

Age (years), mean (SD)	77.02 (10.64)	79.36 (8.38)	76.95 (10.69)	< 0.001
Age≧75 years, n(%)	7140 (65.8)	227 (78.3)	6913 (65.5)	< 0.001
Age 65-74 years, n(%)	2306 (21.3)	44 (15.2)	2262 (21.4)	0.004
Sex (male), n (%)	5886 (54.3)	173 (59.7)	5713 (54.1)	0.060
Comorbidities and medications, n (%)				
  Hypertension	9737 (89.8)	258 (89.0)	9479 (89.8)	0.641
Diabetes mellitus	5004 (46.1)	136 (46.9)	4868 (46.1)	0.794
Heart failure	8056 (74.3)	203 (70.0)	7853 (74.4)	0.108
Prior stroke/TIA	5925 (54.6)	171 (59.0)	5754 (54.5)	0.130
Vascular disease	2099 (19.4)	46 (15.9)	2053 (19.5)	0.101
COPD	5507 (50.8)	151 (52.1)	5356 (50.7)	0.656
Autoimmune diseases	1093 (10.1)	28 (9.7)	1065 (10.1)	0.808
Cancers other than GI tract	1540 (14.2)	42 (14.5)	1498 (14.2)	0.889
Chronic kidney disease	3315 (30.6)	79 (27.2)	3236 (30.7)	0.199
Abnormal liver function	3915 (36.1 )	106 (36.6)	3809 (36.1)	0.871
Use of anti-platelet drugs	1952 (18.0)	53 (18.3)	1899 (18.0)	0.901
Use of NSAIDs	874 (8.1)	22 (7.6)	852 (8.1)	0.764
Alcoholism	379 (3.5)	4 (1.4)	375 (3.6)	0.002
CHA2DS2-VASc score, mean (SD)	5.37 (1.82)	5.52 (1.64)	5.37 (1.83)	0.137
HAS-BLED -score, mean (SD)	4.24 (1.17)	4.30 (1.10)	4.23 (1.17)	0.348






Table 2. Factors associated with the diagnosis of incident GI tract cancers within 1 year after GI bleeding

	Univariate logistic regression	Multivariate logistic regression*
	ORs (95%CI)	 P value	ORs (95%CI)	 P value
Age, per 1 year increment	1.024 (1.011 – 1.036)	< 0.001	1.025 (1.012-1.037)	<0.001
Sex (male)	1.253 (0.988 – 1.589)	0.063	1.356 (1.050-1.700)	0.018
Hypertension	0.915 (0.630 – 1.329)	0.641		
Diabetes mellitus	1.032 (0.817 – 1.303)	0.794		
Heart failure	0.803 (0.622 – 1.036)	0.091	0.803 (0.621-1.038)	0.094
Prior stroke/TIA	1.119 (0.946 – 1.520)	0.133		
Vascular diseases	0.781 (0.568 – 1.074)	0.128		
COPD	1.054 (0.835 – 1.322)	0.656		
Autoimmune diseases	0.952 (0.642 – 1.413)	0.808		
Cancers other than GI tract	1.024 (0.735 – 1.426)	0.889		
Chronic kidney disease	0.847 (0.652 – 1.100)	0.213		
Abnormal liver function	1.020 (0.801 – 1.300)	0.871		
Use of anti-platelet drugs	1.019 (0.754 – 1.379)	0.901		
Use of NSAIDs	0.935 (0.602 – 1.452)	0.764		
Alcoholism	0.380 (0.141 – 1.024)	0.056	0.443 (0.163-1.206)	0.111
CHA2DS2-VASc score	1.046 (0.980 – 1.116)	0.117		
HAS-BLED -score	1.049 (0.949 – 1.160)	0.348		

*Variables with a p value <0.1 were included in the multivariate logistic regression model









	Number of incident GI tract cancers	Number of mortality at 1 year	aHR (95%CI)*	P value
Warfarin	222	115 (51.8%)	-	-




	Number of incident GI tract cancers	Number of mortality at 1 year	aHR (95%CI)*	P value
Warfarin	87	45 (51.7%)	-	-
NOAAOCs	68	16 (23.5%)	0.537 (0.299 – 0.964)	0.037

*Adjustments for the year when GI tract cancers were diagnosed and variables different between patients treated with warfarin and NOACs, including age, sex, CHA2DS2-VASc score, HAS-BLED-score, COPD, autoimmune diseases, cancers other than GI tracts






Figure 1 A flowchart of the enrollment of the study cohort. From January 1, 1996 to December 31, 2015, a total of 142,754 incident AF patients aged > 20 years receiving OACs were identified from NHIRD. Among the study population, 11,632 patients experienced hospitalizations due to GI bleeding and 10,845 of them without priory history of GI tract cancers have constituted the study cohort. Patients were followed up for incident GI cancers up to 1 year.
AF = atrial fibrillation; GI = gastrointestinal; NHIRD = National Health Insurance Research Database; NOACs = non-vitamin K antagonist oral anticoagulants; OACs = oral anticoagulants

Figure 2 Types of GI cancers and the risks of cancers 1 year after GI bleeding. Within 1 year after GI bleeding, 290 (2.67%) patients were diagnosed to have GI tract cancers (esophageal cancer in 10, gastric cancer in 92 and colon cancer in 188). More patients treated with NOACs were diagnosed to have GI cancers than those receiving warfarin (68 in 1,759; 3.87% [NOACs] versus 222 in 9,086; 2.44% [warfarin], p<0.001) with an odds ratio of 1.606 (95% CI 1.208-2.117, p <0.001). 
CI = confidence interval; GI = gastrointestinal; NOACs = non-vitamin K antagonist oral anticoagulants

Figure 3 Percentages of patients diagnosed to have GI cancers within 1 year after GI bleeding stratified by age and gender. The percentages of cancers increased from 0.6% for patients aged < 50 years to 3.10% for those aged > 80 years. For males, the risk was higher among the elderly (age 70-79 years and > 80 years), while a higher risk of GI cancers was observed for females aged < 50 years and > 80 years.
GI = gastrointestinal

Figure 4 Cumulative incidence curves of all-cause mortality after incident GI cancers. Among 290 patients diagnosed to have GI cancers, 131 (45.2%) of them experienced mortality within 1 year. The risk of mortality was lower for patients treated with NOACs compared to those receiving warfarin (23.5% versus 51.8%; log rank p = 0.003)(Figure 4A). Among patients identified between year 2012 – 2015, the 1-year risk of all-cause mortality after incident GI cancers was still lower for patients treated with NOACs compared to warfarin (log rank p = 0.006)(Figure 4B).
GI = gastrointestinal; NOACs = non-vitamin K antagonist oral anticoagulants



Figure 1



Figure 2



Figure 3



Figure 4




20



